Galmed Pharma Announces Continued Advancement Of Aramchol As Potential Disease-Modifying Therapy For Parkinson's Disease, Reporting Significant Progress In Development Of New Aramchol ODF Formulation
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration.In order to improve patient convenience and long-term treatment adherence by
Galmed Pharma is making progress on a new medicine called Aramchol that might help people with Parkinson's disease, and they're working on a new form that's easier for patients to take. When a company keeps making real progress on a medicine, it shows the company is moving forward, though success isn't guaranteed.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.